Advisory Alpha LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

Advisory Alpha LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,208 shares of the company’s stock after buying an additional 195 shares during the quarter. Advisory Alpha LLC’s holdings in Eli Lilly and Company were worth $2,905,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Core Wealth Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory acquired a new position in Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company in the second quarter valued at about $36,000. Frank Rimerman Advisors LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $37,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 364,810 shares of company stock valued at $339,366,198. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

NYSE:LLY opened at $885.56 on Tuesday. The company has a market capitalization of $841.64 billion, a PE ratio of 130.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The stock has a fifty day simple moving average of $896.50 and a 200-day simple moving average of $844.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Barclays upped their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their target price for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.